EU officials clash with Chinese firm on drug factory inspection


By Ben HirschlerLONDON (Reuters) - European medicines regulators have issued a notice that an ingredient for a generic brain cancer drug made in China does not meet manufacturing standards, after inspectors were refused entry to a factory run by Jiangsu Yew Pharmaceutical Co. Ltd.

The incident, reported in a notice published this week on a database maintained by the European Medicines Agency, is the latest example of regulatory problems with bulk pharmaceutical substances manufactured in China.It follows a scandal over tainted supplies of the.

This article is no longer available in our repository.

There could be multiple reasons for this.